Please assess the completion status of the following clinical trial:

Trial Title: PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult aged 18-65~* Able to give informed consent~Exclusion Criteria:~* Known chronic illness~* Hb \<7 at baseline~* Liver function or Creatinine \* 1.5 Upper Limit of Normal~* Urinary tract infection at baseline~* Pregnancy (female participants only)~* Routine medications which interact with study drugs~* Lactose/Gluten intolerance~* Permanent disability impeding study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Azithromycin for Yaws (Type: ACTIVE_COMPARATOR): Patients will receive standard treatment for yaws alone
- IDA for Lymphatic Filariasis (Type: ACTIVE_COMPARATOR): Patients will receive standard IDA (Ivermectin \& Diethylcarbamazine \& Albendazole) treatment for Lymphatic Filariasis alone
- Combination Therapy of Azithromycin for Yaws and IDA for LF (Type: EXPERIMENTAL): Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.

Based on this trial design, predict the completion outcome and termination type (if applicable).